Biotech Stocks Rally After Strong Q3 Earnings: Vaxart and Precigen Lead the Way

viernes, 14 de noviembre de 2025, 2:08 pm ET1 min de lectura
PGEN--

Vaxart and Precigen shares rose after strong Q3 2025 financial results. Vaxart, an oral vaccine developer, added 11%, while Precigen, an immunotherapy maker, surged. The two biotechs posted topline beats with their Q3 2025 financials.

Biotech Stocks Rally After Strong Q3 Earnings: Vaxart and Precigen Lead the Way

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios